<DOC>
	<DOCNO>NCT02626689</DOCNO>
	<brief_summary>This multi-site , prospective , observational study implement β-thalassemia treatment center 5 country ( Italy , Turkey , Greece , Lebanon , Thailand ) . Approximately one two study site identify per country approximately 20 β-thalassemia subject enrol per country ( 10 transfusion dependent ( TD ) 10 Non-transfusion dependent ( NTD ) total approximately 100 subject . This study interfere influence routine clinical management β-thalassemia patient . Outcomes interest collect prospectively 6 month .</brief_summary>
	<brief_title>To Document Burden Illness Quality Life Impact Healthcare Utilization ( Beta ) β-thalassemia Subjects Who Are Transfusion Dependent ( TD ) Non-transfusion Dependent ( NTD ) Receiving Standard Care</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>For transfusion dependent ( TD ) subject : 1 . Male female , &gt; 18 year age time sign informed consent document ( ICF ) ; 2 . Documented diagnosis βthalassemia hemoglobin E/ βthalassemia ; 3 . TD define : ≥6 Red Blood Cells ( RBC ) unit 24 week prior study participation transfusion free period ≥35 day period ; 4 . Performance status : Eastern Cooperative Oncology Group ( ECOG ) score 0 1 . For nontransfusion dependent ( NTD ) subpopulation 1 . Male female , &gt; 18 year age time sign informed consent document ( ICF ) . 2 . Documented diagnosis βthalassemia hemoglobin E/ βthalassemia 3 . NTD define : 0 5 RBC unit receive 24week period prior study participation ( include RBC transfusion unit administer elective surgery ) ; 4 . Most recent hemoglobin ≤10 g/dL ( hemoglobin value ≤ 21 day posttransfusion exclude ) 5 . Performance status : ECOG score 0 1 . For TD Subpopulation : 1 . A diagnosis hemoglobin S/βthalassemia ; 2 . Any significant psychiatric medical condition relate thalassemia would prevent subject participate study ; 3 . Inability read understand local official language ; 4 . Participated another clinical trial ( interventional ) &lt; 30 day prior study participation For NTD Subpopulation : 1 . Received RBC transfusion ≤ 8 week prior study enrollment ; 2 . A diagnosis hemoglobin S/βthalassemia ; 3 . Any significant psychiatric medical condition relate thalassemia would prevent subject participate study ; 4 . Inability read understand local official language ; 5 . Participated another clinical trial ( interventional ) &lt; 30 day prior study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Beta-Thalassemia</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Healthcare Utilization</keyword>
	<keyword>Transfusion dependent ( TD ) β-thalassemia</keyword>
	<keyword>Non-transfusion dependent β-thalassemia</keyword>
	<keyword>Standard care</keyword>
	<keyword>TransQoL</keyword>
	<keyword>SF36v2</keyword>
	<keyword>Fact-An</keyword>
	<keyword>NTD beta-thalassemia PRO</keyword>
</DOC>